Psychopharmacology
January 2, 2019
Thomas Anderson, Rotem Petranker, Daniel Rosenbaum et al.
171 citations
People who currently or formerly microdosed psychedelics like LSD or psilocybin reported lower dysfunctional attitudes and negative emotionality, and higher wisdom, open-mindedness, and creativity compared to non-microdosers. These differences were observed in an online observational study using self-report questionnaires and a creativity task. The findings suggest potential benefits of microdosing, but controlled experiments are needed to confirm safety and clinical efficacy.
Harm Reduction Journal
July 9, 2019
Thomas Anderson, Rotem Petranker, Adam Christopher et al.
130 citations
A mixed-methods study of an active microdosing community categorizes the experiences participants report, identifying high-potential avenues for future scientific research. The resulting taxonomy distills intervention targets from participant reports to help allocate research funding efficiently. Microdosing research complements full-dose psychedelic studies as clinical treatments and neuropharmacological mechanisms are developed. The framework aims to guide researchers and clinicians as experimental microdosing research begins in earnest.
Journal of Psychopharmacology
February 28, 2020
Daniel Rosenbaum, Cory R. Weissman, Thomas Anderson et al.
75 citations
People who microdose psychedelics—taking small, non-hallucinogenic amounts of LSD or psilocybin—are less likely to report a history of substance use disorders or anxiety disorders than non-microdosers, but more likely to report recent recreational substance use. Among 909 participants recruited from Reddit, most microdosers used LSD (59.3%) or psilocybin (25.9%) on a one-day-on, two-days-off schedule. The findings suggest that microdosers differ from non-microdosers in psychiatric and substance-use profiles, and well-designed randomized controlled trials are needed to evaluate safety and potential benefits in clinical populations.
The Canadian Journal of Psychiatry
January 17, 2024
Andrew G. Lee, Daniel Rosenbaum, Daniel Z. Buchman
25 citations
No Summary
AJOB Neuroscience
April 3, 2023
Daniel Rosenbaum, Matthew Cho, Evan Schneider et al.
11 citations
No Summary
Hastings Cent Rep
July 1, 2024
Daniel Rosenbaum, Crystal Hare, Emma Hapke et al.
10 citations
Experiential training—where aspiring therapists undergo psychedelic-assisted therapy themselves—should not be mandatory, according to an ethical analysis applying Sandell et al.'s framework of training therapy functions. The analysis identifies five potential benefits (therapeutic, modeling, empathic, persuasive, and theoretical functions) but weighs them against six domains of risk: physical and psychological harms, negative effects on therapeutic skill, justice and equity concerns, dual relationships, privacy breaches, and undue pressure. Because many programs already include experiential components, the authors argue that the analysis can inform risk-mitigation strategies rather than justify a requirement.
Public health ethics
January 1, 2024
Daniel Buchman, Daniel Rosenbaum
8 citations
The for-profit psychedelic industry is starting to fund scientific research, mirroring practices from tobacco, alcohol, pharmaceutical, and food industries that have created conflicts of interest and harmed population health. Researchers face limited ethics guidance on accepting such sponsorship. A group of clinician scientists applied the PERIL ethical framework to a fictional case of corporate psychedelic funding, finding that financial ties can threaten a research program's purpose, autonomy, and integrity. The commercial determinants of health framework helps understand these industry-healthcare entanglements and offers a population health ethics lens for examining and addressing risks in the nascent psychedelic sector.
Healthcare policy = Politiques de sante
May 1, 2023
Daniel Rosenbaum, Sarah Hales, Daniel Z Buchman
5 citations
Psychedelic therapies show promise for psychological suffering at the end of life, but focusing too much on them may exaggerate the current evidence and pull resources from proven programs. The more urgent policy priority is to fix inequities in access to early, high-quality palliative and psychosocial care. Any discussion of expanding psychedelic access must also center equity concerns.
Pilot and Feasibility Studies
October 28, 2025
Candice Richardson, Cindy Chan, Emily Macgregor et al.
1 citation
A new therapy combining psilocybin with evidence-based psychotherapies for people with advanced cancer, called PEARL therapy, will be tested in an open-label trial with 15 participants. The study will assess whether the therapy is acceptable, feasible, and safe by tracking recruitment, retention, adherence, and serious adverse events, and by collecting self-report questionnaires and qualitative interviews. This research aims to inform policy, training, and clinical guidelines for psychedelic-assisted therapies, which may improve quality of life for those with advanced disease.
Omega
July 10, 2025
Daniel Rosenbaum, Celina Carter, Brandon A Cirella et al.
1 citation
A scoping review of 18 reports found little high-quality evidence on using psychedelic-assisted psychotherapy for grief following death due to advanced illness. Across seven empirical studies, positive outcomes such as reduced grief symptom severity were generally reported, with few adverse events. The literature is informed by differing conceptualizations of grief, adding complexity. The review concludes there is not a strong evidence base to guide clinical recommendations at this time and suggests future work should explicitly situate researchers' positions and integrate grief theory.